Royalty Pharma (RPRX)

Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell i...

Robust quarterly performance with royalty receipts and adjusted EBITDA by +11% and +13%, respectively. New catalysts are emerging with recurrent billion‑dollar transactions and Chinese royalty opportu...

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Marshall Jon...

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street es...

Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago.

Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr...